Kinney Horn - 10 Jan 2022 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role: CHIEF BUSINESS OFFICER
Signature: /s/ John B. Moriarty, Jr., Attorney-in-Fact
Issuer symbol: OLMA
Transactions as of: 10 Jan 2022
Net transactions value: -$25,131
Form type: 4
Filing time: 11 Jan 2022, 19:21:49 UTC
Previous filing: 14 Dec 2021
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OLMA	Common Stock	Options Exercise	$10,838	+5,251	+214%	$2.06^*	7,709	10 Jan 2022	Direct
transaction	OLMA	Common Stock	Sale	$35,969	-5,251	-68%	$6.85	2,458	10 Jan 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OLMA	Stock Option (Right to Buy)	Options Exercise	$0	-5,251	-3.3%	$0.000000	152,289	10 Jan 2022	Common Stock	5,251	$2.06	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2	The weighted average sale price for the transaction reported was $6.85, and the range of prices were between $6.60 and $7.22. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3	The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.